Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics

Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

(2014) A. Garcia-Gomez et al.   CLINICAL CANCER RESEARCH

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma

(2013) Samantha Pozzi et al.   BONE

Cellular Mechanisms of Multiple Myeloma Bone Disease

(2013) Angela Oranger et al.   Clinical & Developmental Immunology

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

(2013) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib

(2013) Shingen Nakamura et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes

(2013) M Colombo et al.   LEUKEMIA

Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1

(2013) L Mirandola et al.   LEUKEMIA

Activin A Suppresses Osteoblast Mineralization Capacity by Altering Extracellular Matrix (ECM) Composition and Impairing Matrix Vesicle (MV) Production

(2013) Rodrigo D. A. M. Alves et al.   MOLECULAR & CELLULAR PROTEOMICS

Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells

(2013) Thibaud André et al.   PLoS One

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy

(2012) E. Terpos et al.   ANNALS OF ONCOLOGY

Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial

(2012) Paul P Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation

(2012) G. Xu et al.   BLOOD

CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease

(2012) D. J. Dairaghi et al.   BLOOD

Impact of bortezomib on bone health in myeloma: A review of current evidence

(2012) Maurizio Zangari et al.   CANCER TREATMENT REVIEWS

Therapeutic approaches to myeloma bone disease: An evolving story

(2012) Vito Longo et al.   CANCER TREATMENT REVIEWS

Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases

(2012) Hua Zhu Ke et al.   ENDOCRINE REVIEWS

Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs

(2012) Enrique M Ocio et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

DangER: protein ovERload. Targeting protein degradation to treat myeloma

(2012) L. I. Aronson et al.   HAEMATOLOGICA

Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth

(2012) Xin Li et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

The Era of Combination Therapy in Myeloma

(2012) Sagar Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

(2012) M A Hurchla et al.   LEUKEMIA

Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway

(2012) S Xu et al.   LEUKEMIA

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation

(2012) N Giuliani et al.   LEUKEMIA

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells

(2012) M Bolzoni et al.   LEUKEMIA

Myeloma plasma cell expression of osteoblast regulatory genes: overexpression of SFRP3 correlates with clinical bone involvement at diagnosis

(2012) Ida Bruun Kristensen et al.   LEUKEMIA & LYMPHOMA

A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy

(2012) Ge Zhang et al.   NATURE MEDICINE

Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis

(2012) Kazuhiro Maeda et al.   NATURE MEDICINE

Latest advances and current challenges in the treatment of multiple myeloma

(2012) Anuj Mahindra et al.   Nature Reviews Clinical Oncology

Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects

(2012) Antonio Garcia-Gomez et al.   PLoS One

Bone cell interactions through Eph/ephrin

(2012) Koichi Matsuo et al.   Cell Adhesion & Migration

Activin Receptor Signaling: A Potential Therapeutic Target for Osteoporosis

(2012) Sutada Lotinun et al.   Current Molecular Pharmacology

Impairment in Immunomodulatory Function of Mesenchymal Stem Cells from Multiple Myeloma Patients

(2011) Bingzong Li et al.   ARCHIVES OF MEDICAL RESEARCH

Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease

(2011) S. D'Souza et al.   BLOOD

Immunomodulatory properties and therapeutic application of mesenchymal stem cells

(2011) M. Shi et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects

(2011) M. R. Reagan et al.   CLINICAL CANCER RESEARCH

Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma

(2011) Noopur Raje et al.   CLINICAL CANCER RESEARCH

Genomics in Multiple Myeloma

(2011) Nikhil C. Munshi et al.   CLINICAL CANCER RESEARCH

The IRE1α–XBP1 pathway is essential for osteoblast differentiation through promoting transcription of Osterix

(2011) Takahide Tohmonda et al.   EMBO REPORTS

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

(2011) Michel Delforge et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

CCR1 as a target for multiple myeloma

(2011) Sonia Vallet et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Update on Wnt signaling in bone cell biology and bone disease

(2011) David G. Monroe et al.   GENE

Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial

(2011) J. A. Perez-Simon et al.   HAEMATOLOGICA

Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors

(2011) Daniele Tibullo et al.   HEMATOLOGICAL ONCOLOGY

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy

(2011) Evangelos Terpos et al.   INTERNATIONAL JOURNAL OF CANCER

BMP2 Protein Regulates Osteocalcin Expression via Runx2-mediatedAtf6Gene Transcription

(2011) Won-Gu Jang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation

(2011) Grace L. Lin et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma

(2011) V Ramakrishnan et al.   LEUKEMIA

Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation

(2011) D Xu et al.   LEUKEMIA

A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function

(2011) S Vallet et al.   LEUKEMIA

Myeloma cells suppress osteoblasts through sclerostin secretion

(2011) S Colucci et al.   Blood Cancer Journal

Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma

(2011) Feng Chen et al.   CELLULAR ONCOLOGY

Culture media for the differentiation of mesenchymal stromal cells

(2010) Corina Vater et al.   Acta Biomaterialia

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays

(2010) Karène Mahtouk et al.   BMC CANCER

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts

(2010) Hichame Id Boufker et al.   BMC CANCER

A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys

(2010) Sutada Lotinun et al.   BONE

TGF-β-related mechanisms of bone destruction in multiple myeloma

(2010) Toshio Matsumoto et al.   BONE

Advances in the understanding of myeloma bone disease and tumour growth

(2010) Shmuel Yaccoby   BRITISH JOURNAL OF HAEMATOLOGY

Angiogenic Activity of Mesenchymal Stem Cells in Multiple Myeloma

(2010) Xiaofang Wang et al.   CANCER INVESTIGATION

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

(2010) Lawrence R. Dick et al.   DRUG DISCOVERY TODAY

Endoplasmic Reticulum Stress Response Mediated by the PERK-eIF2α-ATF4 Pathway Is Involved in Osteoblast Differentiation Induced by BMP2

(2010) Atsushi Saito et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

(2010) Andrew D Chantry et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

(2010) Desmond Padhi et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton

(2010) Diptiman Chanda et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Macrophage inflammatory protein-1α induces osteoclast formation by activation of the MEK/ERK/c-Fos pathway and inhibition of the p38MAPK/IRF-3/IFN-β pathway

(2010) Masanobu Tsubaki et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

(2010) E Terpos et al.   LEUKEMIA

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

(2010) R A Kyle et al.   LEUKEMIA

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells

(2010) Stephanie Markovina et al.   Molecular Cancer

Combined Inhibition of Notch Signaling and Bcl-2/Bcl-xL Results in Synergistic Antimyeloma Effect

(2010) M. Li et al.   MOLECULAR CANCER THERAPEUTICS

Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts

(2010) Y-C Lee et al.   ONCOGENE

TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth

(2010) Kyoko Takeuchi et al.   PLoS One

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

(2010) S. Vallet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone

(2010) Xin Li et al.   STEM CELLS

Mesenchymal stem cells: Molecular characteristics and clinical applications

(2010) Cristina Sancricca   World Journal of Stem Cells

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

(2009) E. Terpos et al.   ANNALS OF ONCOLOGY

The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth

(2009) A. Pennisi et al.   BLOOD

A monoclonal gammopathy precedes multiple myeloma in most patients

(2009) B. M. Weiss et al.   BLOOD

Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease

(2009) A. Kukreja et al.   BLOOD

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

(2009) M. Fulciniti et al.   BLOOD

NOTCHing the bone: Insights into multi-functionality

(2009) Feyza Engin et al.   BONE

 3 Integrin Subunit Mediates the Bone-Resorbing Function Exerted by Cultured Myeloma Plasma Cells

(2009) M. Tucci et al.   CANCER RESEARCH

The unfolded protein response and its relevance to connective tissue diseases

(2009) Raymond P. Boot-Handford et al.   CELL AND TISSUE RESEARCH

Multiple Myeloma Bone Marrow Niche

(2009) Grzegorz Basak et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease

(2009) Katia Todoerti et al.   EXPERIMENTAL HEMATOLOGY

Bidirectional Signaling through EphrinA2-EphA2 Enhances Osteoclastogenesis and Suppresses Osteoblastogenesis

(2009) Naoko Irie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pro-Inflammatory Cytokines TNF-Related Weak Inducer of Apoptosis (TWEAK) and TNFα Induce the Mitogen-Activated Protein Kinase (MAPK)-Dependent Expression of Sclerostin in Human Osteoblasts*

(2009) Cristina Vincent et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Myeloma Bone Disease

(2009) Ralph D Sanderson et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

(2009) M Garayoa et al.   LEUKEMIA

Bisphosphonates: Mechanism of Action and Role in Clinical Practice

(2009) Matthew T. Drake et al.   MAYO CLINIC PROCEEDINGS

Pharmacologic Inhibition of the TGF-β Type I Receptor Kinase Has Anabolic and Anti-Catabolic Effects on Bone

(2009) Khalid S. Mohammad et al.   PLoS One

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

(2008) Angela Pennisi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells

(2008) Barbara Zdzisińska et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth

(2008) Y.-W. Qiang et al.   BLOOD

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma

(2008) Y.-W. Qiang et al.   BLOOD

Validation of PDGFR  and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib

(2008) A. M. L. Coluccia et al.   BLOOD

The pathogenesis of the bone disease of multiple myeloma

(2008) Claire M. Edwards et al.   BONE

CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3  and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions

(2008) N. Giuliani et al.   CANCER RESEARCH

Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells

(2008) F. Silvestris et al.   CLINICAL CANCER RESEARCH

Notch Inhibits Osteoblast Differentiation and Causes Osteopenia

(2008) Stefano Zanotti et al.   ENDOCRINOLOGY

Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification

(2008) Soraya Carrancio et al.   EXPERIMENTAL HEMATOLOGY

Mesenchymal cells recruit and regulate T regulatory cells

(2008) M DIIANNI   EXPERIMENTAL HEMATOLOGY

Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

(2008) Deborah J Heath et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women*

(2008) Jon Ruckle et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of pathologic fractures on survival in multiple myeloma patients: a case control study

(2008) Mehmet Sonmez et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Notch inhibition blocks multiple myeloma cell-induced osteoclast activation

(2008) R Schwarzer et al.   LEUKEMIA

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA

The Association of Notch2 and NF- B Accelerates RANKL-Induced Osteoclastogenesis

(2008) H. Fukushima et al.   MOLECULAR AND CELLULAR BIOLOGY

Dimorphic effects of Notch signaling in bone homeostasis

(2008) Feyza Engin et al.   NATURE MEDICINE

A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity

(2008) R. S. Pearsall et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption

(2008) Natalie A. Sims et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma

(2007) Ya-Wei Qiang et al.   BONE

Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA)

(2007) Monica Hecht et al.   EXPERIMENTAL CELL RESEARCH

Human Mesenchymal Stem Cells Inhibit Neutrophil Apoptosis: A Model for Neutrophil Preservation in the Bone Marrow Niche

(2007) Lizzia Raffaghello et al.   STEM CELLS